Zanubrutinib (BGB-3111), an investigational small molecule inhibitor of BTK, showed promising activity in patients with Waldenström macroglobulinemia (WM), according to updated results presented at the 2018 European Hematology Association Congress.
First author Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of… Continue reading
Ibrutinib is active in previously treated Waldenstro¨m macroglobulinemia (WM). MYD88 mutations
(MYD88MUT) and CXCR4 mutations (CXCR4MUT) affect ibrutinib response. We report on a prospective
study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect
of… Continue reading
In the article that accompanies this editorial, Treon and colleagues
1 report on 30 newly diagnosed patients with Waldenstr¨om
macroglobulinemia (WM) treated with ibrutinib. Clinically relevant
responses were seen in all patients. Responses occurred rapidly
with an 18-month… Continue reading
A type of non-Hodgkin lymphoma, Waldenström macroglobulinemia is a rare, slow-growing lymphoproliferative disorder that is estimated to affect only 1,000 to 1,500 individuals each year in the… Continue reading
Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc announced that the US Food and Drug Administration (FDA) has granted Priority Review for a supplemental New Drug Application (sNDA) for the company’s Waldenström’s macroglobulinemia combination therapy, ibrutinib (IMBRUVICA)… Continue reading
The following link is to the Cancer Therapy Advisor website featuring the following video
Meletios Dimopoulos, MD, discusses his findings at the ASCO 2018 meeting in Chicago.
Treatment with a combination of ibrutinib and rituximab improved progression-free survival (PFS) over rituximab alone in patients with Waldenström macroglobulinemia (WM), according to results… Continue reading